In breast cancer, the NT5DC2 was upregulated and high NT5DC2 expression exhibited inferior prognosis of breast cancer patients, and the NT5DC2 expression was correlated with advanced Scarff-Bloom-Richardson grades and higher Nottingham Prognostic Index values.[19] Schulze and colleagues studied the levels of NT5DC2 in 1925 nonsmall-cell lung cancer (NSCLC) patients (squamous cell tumor [48%], adenocarcinoma [35%], large cell histology [17%]), and discovered that the NT5DC2 mRNA levels were higher in squamous cell tumor compared to adenocarcinoma. The gene discussed is NT5DC2; the disease is adenocarcinoma.